Company Focus
Lonza
Latest Lonza News
Biotechnology
German biotech Ethris, a company developing RNA therapeutics and vaccines, and Swiss contract development and manufacturing organization Lonza, have announced a collaboration. 7 April 2025
Cell & Gene Therapy News
Insights
Company Spotlight
A biopharma company utilising small interfering RNAs (siRNAs) to improve and expand the reach of RNAi-based medicines.
Latest News & Features of interest to Lonza
Pharmaceutical
US pharma major Bristol Myers Squibb is planning a massive $40 billion investment in the country over the next five years. 7 May 2025
Biotechnology
US healthcare giant Johnson & Johnson has presented data from its Phase III LUMEOS study and disclosed that the trial did not meet its primary endpoint. 6 May 2025
Biotechnology
Some $45 million has been raised in a Series B financing round by Nuevocor, an IND-stage biotech developing therapies for genetic cardiomyopathy, a largely unaddressed condition, by targeting the underlying mechanical defects. 6 May 2025
Biotechnology
Portugal-based Hovione and Firstgene Life Sciences, a portfolio company of the Swiss incubator Xlife Sciences, today announced a strategic collaboration to advance Hovione’s proprietary virus-like particle drug delivery platform for the targeted treatment of hepatocellular carcinoma (HCC), a therapeutic indication developed by Firstgene. 6 May 2025
Biotechnology
Benchtop cell factory company Astraveus has entered into a strategic partnership with The Netherlands Center for the Clinical Advancement of Stem Cell and Gene Therapies (NecstGen). 6 May 2025
Biotechnology
T-cell immunotherapies (TCI) are redefining cancer care, with chimeric antigen receptor T-cell (CAR-T) therapies witnessing significant momentum. 5 May 2025
Biotechnology
The global dermatological cell and gene therapy (CGT) market is poised for exceptional growth at a compound annual growth rate (CAGR) of 31.3%, with sales projected to rise from $291 million in 2024 to $1.5 billion in 2030. 2 May 2025
Biotechnology
Early-stage biotech Nova Anchora has secured a new investment to move its lead therapy for epidermolysis bullosa (EB) closer to clinical trials. 29 April 2025
Biotechnology
Galapagos has appointed Henry Gosebruch as chief executive of its upcoming oncology spin-off, marking a major step in the company’s planned division into two focused businesses. 22 April 2025
Biotechnology
US gene therapy company bluebird bio announced that after three weeks of engagement, including a timeline extension, Ayrmid Pharma has not submitted a binding proposal to acquire bluebird and has not obtained necessary financing. 17 April 2025
Latest In Brief for Lonza
Biotechnology
Kite, a Gilead Sciences company, will share four posters that add to the growing body of evidence to support the clinical use of its chimeric antigen receptor (CAR) T-cell therapy portfolio, at the 7th European CAR T-cell Meeting, 6-8 February 2025, Strasbourg, France. 8 February 2025
Latest Cell & Gene Therapy Ones To Watch News
German biotech TQ Therapeutics today announced the acquisition of Juno Therapeutics GmbH, a cell therapy company, through a share purchase agreement. Financial terms of the agreement were not disclosed. 28 May 2025
17 April 2025
29 March 2025
Cell & Gene Therapy Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze